EGFR Activating Mutation clinical trials at UC Davis
1 research study open to eligible people
A Study of Experimental Combination Treatment With Osimertinib and Navitoclax For EGFR-Positive Non-small Cell Lung Cancer
open to eligible people ages 18 years and up
This phase Ib trial studies the side effects and best dose of osimertinib and navitoclax when given together and to see how well they work in treating patients with previously treated epidermal growth factor receptor (EGFR)-positive non-small cell lung cancer that has spread to other places in the body or has not responded to previous treatment with initial EGFR kinase inhibitor. Osimertinib and navitoclax may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Sacramento, California and other locations